Date of Award
M.S. in Pharmaceutical Science
University of Mississippi
The goal of the present study was to develop a nanoemulsion (NE) system for efficient and prolonged delivery of Fingolimod Hydrochloride (FTY720; FT), to the posterior segment of the eye through the topical route. FT is a sphingosine-1-phosphate receptor agonist, an immunosuppressive agent. FT loaded NE (FT-NE) formulations were prepared with the homogenization method, using Soybean oil as lipid, Tween® 80 and Poloxamer 188 as surfactants. FT-NE were optimized based on particle size, zeta potential (ZP), Polydispersity Index (PDI) and assay. optimized FT-NE formulation were further evaluated for in vitro release and transcorneal in comparison with FT solution (FT-S) formulation, sterilization and stability studies. Optimized FT-NE formulation had a drug load of 0.3% w/v, showed a particle size, PDI, ZP and assay of 174.6±1.5 nm, 0.22 ± 0.01, 32.8 ± 1.9 mV and 97.5 ± 2.5%, respectively. The filtration studies indicated negligible process loss (< 1%) when filtered through PES 0.22µm filters. FT-NE formulation was stable for 45 days and 90 days at room temperature and refrigerator conditions, respectively. In vitro release studies showed 50.1 ± 6.3% and 79.2 ± 2.6% drug release from FT-NE and FT-S over 24 h, indicating sustained release. Transcorneal permeation studies showed 2-fold and 5-fold increase between FT-S (0.15%) and FT-NE-S3 and FT-S (0.3%) and FT-NE-S2 formulations, respectively. The results from this study demonstrated that the NE formulation can serve as a viable platform for topical delivery of FT.
Kashikar, Rama Avinash, "Formulation And Optimization Of Fingolimog Hydrochloride Nanoemulsion" (2020). Electronic Theses and Dissertations. 1831.
Available for download on Tuesday, August 31, 2021